Oropharyngeal cancer arises from the squamous epithelium of the oropharynx, anatomically encompassing the palatine tonsils (most common site), base of tongue (lingual tonsils), soft palate including uvula, and posterior pharyngeal wall. Over 90% of these tumors are squamous cell carcinomas. The epidemiology has undergone profound transformation: while tobacco and alcohol-related disease has declined, HPV-associated oropharyngeal cancer has risen dramatically, now constituting 70-80% of cases in many developed countries. HPV-16 is the predominant subtype, with infection acquired primarily through oral sexual contact and a long latent period before malignant transformation.
HPV-positive oropharyngeal cancer demonstrates distinctly different clinical and biological characteristics compared to HPV-negative disease. Patients tend to be younger (40-60 years), with less tobacco/alcohol exposure, often presenting with relatively asymptomatic neck masses representing cystic cervical lymph node metastases despite small primary tumors. Despite frequent nodal metastasis at presentation, HPV-positive tumors show remarkably favorable prognosis with 3-year survival rates of 80-90% versus 50-60% for HPV-negative disease. This biological distinction has prompted separate AJCC 8th edition staging systems, with HPV-positive disease assigned more favorable stage groupings.
Modern diagnosis includes thorough head and neck examination, fiberoptic nasopharyngolaryngoscopy, biopsy of primary tumor or fine-needle aspiration of metastatic node, p16 immunohistochemistry (highly sensitive surrogate for HPV status), HPV in situ hybridization for confirmation, and contrast-enhanced CT or MRI for staging. PET-CT identifies distant metastases. Treatment paradigms have evolved significantly: traditional concurrent chemoradiation remains standard for many cases, but transoral robotic surgery (TORS) enables minimally invasive primary tumor removal with neck dissection followed by risk-adapted adjuvant therapy. Active investigation of de-escalation strategies seeks to maintain excellent HPV-positive disease outcomes while reducing late toxicity through reduced radiation doses, alternative chemotherapy regimens, and surgery-only protocols for favorable cases.